"Today marks a pivotal moment in the evolution of structural heart therapy," Capstan Medical CEO Maggie Nixon said.

Buoyed by $110m in funding three months ago, Capstan Medical has reported the first-in-human cases with the mitral technology ...

Mitral valve annuloplasty devices are expected to see the highest growth in the region. Increased investments in healthcare ...

Capstan Medical announced its first in-human cardiac valve replacements using its catheter-based robotic surgical platform.

Capstan CEO Maggie Nixon discusses first-in-human feedback, the all-at-once approach, regulatory strategy and the tricuspid ...

The money will support an ongoing pivotal trial of 4C Medical Technologies' transcatheter mitral valve replacement device in ...

Development of minimally invasive procedures to address mitral and tricuspid disease has lagged progress in aortic valve treatment, where Edwards Lifesciences and Medtronic are the leaders in a market ...

Impact of sex on in-hospital mortality and 90-day readmissions in patients undergoing transcatheter mitral valve replacement (TMVR): Analysis from the nationwide readmission database.

Pi-Cardia today announced the first commercial procedures with its ShortCut leaflet modification device for enabling heart ...

The hospital also offers transcatheter mitral valve replacement (TMVr) for mitral regurgitation and transcatheter aortic valve replacement (TAVR) for aortic stenosis. The hospital recently ...

C Medical Technologies Inc. raised $175 million in a series D financing round led by Boston Scientific Corp. The financing will support the regulatory trials and commercialization of the Altavalve ...